KR101940569B1 - Pharmaceutical composition comprising bazedoxifene or a pharmaceutically acceptable salt thereof - Google Patents

Pharmaceutical composition comprising bazedoxifene or a pharmaceutically acceptable salt thereof Download PDF

Info

Publication number
KR101940569B1
KR101940569B1 KR1020170063942A KR20170063942A KR101940569B1 KR 101940569 B1 KR101940569 B1 KR 101940569B1 KR 1020170063942 A KR1020170063942 A KR 1020170063942A KR 20170063942 A KR20170063942 A KR 20170063942A KR 101940569 B1 KR101940569 B1 KR 101940569B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
composition according
sodium
starch
acid
Prior art date
Application number
KR1020170063942A
Other languages
Korean (ko)
Other versions
KR20180128612A (en
Inventor
박영준
김주은
최숙
임서은
Original Assignee
아주대학교산학협력단
(주)아이엠디팜
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아주대학교산학협력단, (주)아이엠디팜 filed Critical 아주대학교산학협력단
Priority to KR1020170063942A priority Critical patent/KR101940569B1/en
Priority to PCT/KR2018/005470 priority patent/WO2018216933A1/en
Publication of KR20180128612A publication Critical patent/KR20180128612A/en
Application granted granted Critical
Publication of KR101940569B1 publication Critical patent/KR101940569B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Abstract

The present invention provides a pharmaceutical composition comprising a basic amino acid as a active ingredient and a pharmaceutically acceptable salt thereof (and optionally a vitamin D derivative) and a stabilizing agent, and does not contain an antioxidant. Since the pharmaceutical composition of the present invention can remarkably lower the generation of a soft substance originating from a pen at the time of bar administration, it has excellent stability and can therefore be useful for a long period of time.

Description

[0001] The present invention relates to pharmaceutical compositions comprising bazedoxifene or a pharmaceutically acceptable salt thereof,

The present invention relates to a pharmaceutical composition comprising as an active ingredient a bar-cleaving ciphen or a pharmaceutically acceptable salt thereof and optionally a vitamin D derivative. More particularly, the present invention relates to a pharmaceutical composition comprising a basic aminoglycoside or a pharmaceutically acceptable salt thereof (and optionally a vitamin D derivative) as a active ingredient and a basic amino acid as a stabilizer, .

The bazedoxifene is a compound of the formula (I) wherein the chemical name is 1- [4- (2-azepan-1-yl-ethoxy) -benzyl] -2- (4-hydroxy- 5-ol, known as a selective estrogen receptor modulator. Bar adipocyte is in the form of acetate, which is used to treat osteoporosis in postmenopausal women [Vivienne TM (Korea Pfizer)]. VivienneTM TM contains ascorbic acid to ensure stability of baracetate penacetate but has a somewhat shorter period of use of 18 months due to its low stability.

Korean Patent Registration No. 10-1584674 (WO 2007/024961) discloses a non-aqueous pharmaceutical composition containing 15% by weight or less of an antioxidant such as ascorbic acid and a preparation method without containing a surfactant .

In addition, U.S. Patent Publication No. US2011 / 0165241 discloses that there is a problem that a tablet composition containing a basilixin acetic acid salt, ascorbic acid, and hydroxypropylmethylcellulose shows a decrease in dissolution stability during long-term storage . U.S. Patent Publication No. US2011 / 0165241 discloses the use of vitamin E, vitamin E TPGS, propyl gallate, citric acid or butylated hydroxyanisole / butylated hydroxytoluene instead of ascorbic acid as a means for solving the problem .

In addition, Korean Patent Laid-Open Publication No. 10-2007-0018900 (WO 2005/099677) discloses a solid dispersion containing a benzoxifenacetic acid salt for improving bioavailability.

However, when a solid preparation containing bar steroid ciphen or a pharmaceutically acceptable salt thereof is stored without using a stabilizing agent such as an antioxidant, The substance is out of the reference range. In addition, solid preparations containing a bar stabilizing cine or a pharmaceutically acceptable salt thereof together with a stabilizer such as an antioxidant have a relatively low stability (that is, a short use period of 18 months) so that they can be stored for a long period of time Lt; RTI ID = 0.0 > and / or < / RTI >

The present inventors have carried out various studies to develop a solid preparation containing an improved ciprofen or a pharmaceutically acceptable salt thereof with improved stability. In particular, the present inventors have conducted various studies to develop a pharmaceutical agent capable of improving the stability by minimizing the generation of a soft substance derived from a pen when a bar is taken for a long period of time. As a result, when a specific stabilizing agent, that is, a basic amino acid is used as a stabilizer instead of an antioxidant such as ascorbic acid, vitamin E, and butylated hydroxytoluene conventionally used as a stabilizer, Can be significantly lowered. In addition, it has been found that even in the case of a preparation containing vitamin D derivatives for osteoporosis patients whose vitamin D intake is insufficient, the basic amino acid can remarkably lower the generation of the pendant derived from the pen when the bar is removed.

Accordingly, it is an object of the present invention to provide a pharmaceutical composition comprising a basic aminoglycoside or a pharmaceutically acceptable salt thereof (and optionally a vitamin D derivative) and a basic amino acid as a stabilizer, which does not comprise an antioxidant .

According to one aspect of the present invention, there is provided a pharmaceutical composition comprising as an active ingredient a bar-cleaving ciphen or a pharmaceutically acceptable salt thereof; And a basic amino acid as a stabilizer, and is free from an antioxidant.

The pharmaceutical composition of the present invention can contain, as active ingredients, colecalciferol, calcitriol, calcipotriol, tacalcitol, maxacalcitol, paricalcitol, ), And seocalcitol. ≪ RTI ID = 0.0 > [0040] < / RTI >

In the pharmaceutical composition of the present invention, the pharmaceutically acceptable salt of the bar remodeling cigarette may be penacetic acid salt at the time of bar administration, and the vitamin D derivative may be cholecalciferol.

In the pharmaceutical composition of the present invention, the basic amino acid may be selected from the group consisting of histidine, arginine, and lysine, preferably histidine. The basic amino acid may be present in the range of 0.1 to 20.0 wt%, preferably 0.5 to 5 wt%, based on the total weight of the composition.

The pharmaceutical composition of the present invention can be used as a pharmaceutical composition containing lactose, mannitol, isomalt, microcrystalline cellulose, dextran, maltodextrin, sorbitol, glucose, pregelatinized starch, potato starch, corn starch, light anhydrous silicic acid, colloidal silicon dioxide, A diluent selected from the group consisting of calcium, carboxymethylcellulose, carboxyethylcellulose, hydroxyethylcellulose, and magnesium aluminum silicate; At least one disintegrant selected from the group consisting of starch, pregelatinized starch, sodium starch glycolate, croscarmellose sodium, crospovidone, carboxymethylcellulose calcium, carboxymethylcellulose sodium, alginic acid, and sodium alginate; And stearic acid or its salts, talc, magnesium / aluminum silicate, glyceryl behenate, hard castor oil, vegetable castor oil, polyethylene glycol, glyceryl monostearate, and sucrose stearic acid And at least one surfactant selected from the group consisting of esters. For example, the pharmaceutical compositions of the present invention may have the form of tablets, which may be further film coated.

In one embodiment, the pharmaceutical composition of the present invention comprises 22.6 mg of penic acid acetate per bar, 10.0 to 90.0 mg of pregelatinized starch, 26.4 to 199.4 mg of microcrystalline cellulose, 1.0 to 15.0 mg of colloidal silicon dioxide, 15.0 mg of lactose monohydrate, The pharmaceutical composition may be in the form of a tablet containing 131.1 mg, histidine 0.5 to 20.0 mg, sodium starch glycolate 3.0 to 26.0 mg, and sodium stearyl fumarate 2.0 to 15.0 mg, preferably polyvinyl alcohol And a coating layer formed on the tablet.

In another embodiment, the pharmaceutical composition of the present invention comprises 22.6 mg of penic acid acetate per bar, 800 to 5600 IU of cholecalciferol, 10.0 to 90.0 mg of pregelatinized starch, 26.38 to 199.38 mg of microcrystalline cellulose, The pharmaceutical composition may be in the form of a tablet containing 1.0 to 15.0 mg of lactose, 15.0 to 118.0 mg of lactose, 0.5 to 20.0 mg of histidine, 3.0 to 26.0 mg of sodium starch glycolate, and 2.0 to 15.0 mg of sodium stearyl fumarate, May be a pharmaceutical composition in the form of a skin-cleanser in which a film coating layer containing polyvinyl alcohol is formed on the tablet.

When a specific stabilizing agent, that is, a basic amino acid, is used as a stabilizer instead of an antioxidant such as ascorbic acid, vitamin E and butylated hydroxytoluene conventionally used as a stabilizer, It can be lowered by the present invention. It has also been found by the present invention that, even in the case of a preparation further containing a vitamin D derivative, the basic amino acid can significantly reduce the generation of the pendent originating from the pen at the time of bar removal. Therefore, a single preparation containing the bar-treatment ciphen or its pharmaceutically acceptable salt according to the present invention as an active ingredient and the bar-cleansing ciphen or its pharmaceutically acceptable salt and vitamin D derivative according to the present invention, Can have useful stability for a long period of time.

The present invention relates to a pharmaceutical composition comprising as an active ingredient a bar-cleaving ciphen or a pharmaceutically acceptable salt thereof; And a basic amino acid as a stabilizer, and does not contain an antioxidant.

In addition, the pharmaceutical composition of the present invention can contain, as active ingredients, colecalciferol, calcitriol, calcipotriol, tacalcitol, maxacalcitol, paricalcitol, and seocalcitol. The vitamin D derivative may further include one or more vitamin D derivatives selected from the group consisting of paricalcitol, and seocalcitol.

 In the pharmaceutical composition of the present invention, the pharmaceutically acceptable salt of the bar remodeling cine may be, but is not limited to, penic acid acetic acid salt at the time of bar removal. The bar-cleansing cine or its pharmaceutically acceptable salt may be used in a therapeutically effective amount, for example in the range of 1 to 100 mg, preferably in the range of 10 to 30 mg, , More preferably about 20 mg (about 22.6 mg as a barcodeine cyphenate salt). In addition, the vitamin D derivative may preferably be cholecalciferol. The vitamin D derivatives such as cholecalciferol can be used in therapeutically effective amounts, for example in the range of 50 to 5,600 IU per unit of agent, preferably in the range of 400 to 2,000 IU. About 800 IU of cholecalciferol has a mass of about 0.02 to 8 mg according to the activity per gram of cholecalciferol (40,000,000 IU / g to 100,000 IU / g).

The pharmaceutical composition of the present invention may contain conventional antioxidants such as ascorbic acid or a salt thereof (e.g., sodium salt, palmitate), vitamin E, propyl gallate, butylated hydroxytoluene (BHT ), Butylated hydroxyanisole (BHA), etc.), it is possible to remarkably lower the generation of the pendant originating from the pen at the time of bar removal by containing a basic amino acid stabilizer. As described in the following test example, a preparation containing a basic amino acid such as histidine as a stabilizer minimizes the generation of a substance for a long period of time (for example, about 4 weeks) under severe conditions (60 ° C, 75% RH) And thus exhibits excellent stability. The basic amino acid may be selected from the group consisting of histidine, arginine, and lysine, preferably histidine. The basic amino acid may be present in the range of 0.1 to 20.0 wt%, preferably 0.5 to 5 wt%, based on the total weight of the composition.

The pharmaceutical composition of the present invention may contain additives such as diluents, disintegrants, lubricants and the like commonly used in the field of pharmaceuticals. Examples of the diluent include lactose (including hydrate such as lactose hydrate), mannitol, isomalt, microcrystalline cellulose, dextran, maltodextrin, sorbitol, glucose, pregelatinized starch, potato starch, corn starch, Silicon dioxide, crystalline cellulose, anhydrous calcium phosphate, carboxymethylcellulose, carboxyethylcellulose, hydroxyethylcellulose, and magnesium aluminum silicate. Examples of the disintegrant include starch, pregelatinized starch, sodium starch glycolate, croscarmellose sodium, crospovidone, carboxymethylcellulose calcium, carboxymethylcellulose sodium, alginic acid, sodium alginate and the like. Examples of the lubricant include sodium stearyl fumarate, colloidal silicon dioxide, silica, stearic acid or a salt thereof, talc, magnesium / aluminum silicate, glyceryl behenate, hard castor oil, vegetable castor oil, polyethylene glycol, glyceryl monostearate Sucrose stearic acid ester, and the like. For example, the pharmaceutical compositions of the present invention may comprise a combination of lactose and microcrystalline cellulose as diluents; A combination of pregelatinized starch and starch glycolic acid sodium as a disintegrant; As a lubricant, a combination of sodium stearyl fumarate and colloidal silicon dioxide. The amount of the additive such as the diluent, disintegrant, lubricant and the like is not particularly limited and may be suitably selected by those skilled in the art. For example, the diluent may be in the range of 30 to 90 wt.%, The disintegrant may be in the range of 1 to 20 wt.% Based on the total weight of the composition, the lubricant may be in the range of 0.5 to 5 wt. But is not limited thereto.

The pharmaceutical composition of the present invention may be a solid dosage form such as an acid, a granule, a capsule, or a tablet, preferably in the form of a capsule or a tablet, and more preferably in the form of a tablet. In addition, the pharmaceutical composition of the present invention may be in the form of a shellac-tablet, for example, a film-coating base containing polyvinyl alcohol (for example, Opadyl TM 85F42129 (Colorcona) - It can be in the form of tablets.

In one embodiment, the pharmaceutical composition of the present invention comprises 22.6 mg of penic acid acetate per bar, 10.0 to 90.0 mg of pregelatinized starch, 26.4 to 199.4 mg of microcrystalline cellulose, 1.0 to 15.0 mg of colloidal silicon dioxide, 15.0 mg of lactose monohydrate, The pharmaceutical composition may be in the form of a tablet containing 131.1 mg, histidine 0.5 to 20.0 mg, sodium starch glycolate 3.0 to 26.0 mg, and sodium stearyl fumarate 2.0 to 15.0 mg, preferably polyvinyl alcohol And a coating layer formed on the tablet.

In another embodiment, the pharmaceutical composition of the present invention comprises 22.6 mg of penic acid acetate per bar, 800 to 5600 IU of cholecalciferol, 10.0 to 90.0 mg of pregelatinized starch, 26.38 to 199.38 mg of microcrystalline cellulose, The pharmaceutical composition may be in the form of a tablet containing 1.0 to 15.0 mg of lactose, 15.0 to 118.0 mg of lactose, 0.5 to 20.0 mg of histidine, 3.0 to 26.0 mg of sodium starch glycolate, and 2.0 to 15.0 mg of sodium stearyl fumarate, May be a pharmaceutical composition in the form of a skin-cleanser in which a film coating layer containing polyvinyl alcohol is formed on the tablet.

The method of preparing a pharmaceutical composition of the present invention comprises the steps of: mixing a bar or a pharmaceutically acceptable salt thereof (and optionally a vitamin D derivative), a basic amino acid, and a pharmaceutically acceptable additive; And filling the resulting mixture into a capsule to obtain a capsule, or tableting the resulting mixture to obtain a tablet. Further, as described above, if necessary, a step of forming a film coating layer with a film-coating base containing polyvinyl alcohol (for example, Opadry TM 85F42129 (Colorcona)) may be further included. The mixing may be performed through a plurality of mixing processes in which all the components are mixed through one mixing process or a mixture of a plurality of components is mixed with the remaining components. The mixing process, the capsule filling process, the tableting process, the film coating process, and the like may be performed according to a conventional method known in the pharmaceutical industry.

Hereinafter, the present invention will be described in more detail through examples and test examples. However, the following examples and test examples are provided for illustrating the present invention, and the present invention is not limited thereto.

Example  One. Bar Admiral Pien  Preparation of tablets containing acetic acid salts

Tablets containing the penic acid acetic acid salt according to the contents and compositions shown in Table 1 below were prepared. The content of each component in Table 1 represents the refined sugar content (mg). (22.6 mg per tablet, 20 mg as a bar sterilizer), colloidal silicon dioxide and histidine, followed by addition of microcrystalline cellulose, pregelatinized starch and sodium starch glycolate, followed by mixing. The resulting mixture was sieved with a 30-mesh sieve, and the lactose hydrate was further added thereto and mixed. The resulting mixture was mixed with sodium stearyl fumarate. The resulting mixture was triturated to produce 290 mg of a tablet. The obtained tablets were coated with Opadry TM 85F42129 (Colorcon) to prepare film-coated tablets.

ingredient EXAMPLES (mg / tablet) 1-1 1-2 1-3 1-4 1-5 Bar adecinoxyacetate 22.6 22.6 22.6 22.6 22.6 Pregelatinized starch 45.0 45.0 10.0 90.0 90.0 Microcrystalline cellulose 89.4 73.4 199.4 26.4 26.4 Colloidal silicon dioxide 9.0 9.0 1.0 1.0 15.0 Lactose baggage 90.0 90.0 15.0 122.5 131.1 Histidine 5.0 20.0 5.0 0.5 0.5 Starch glycolate sodium 21.0 21.0 26.0 3.0 3.0 Sodium stearyl fumarate 9.0 9.0 2.0 15.0 15.0 Opadry TM 85F42129 9.0 9.0 9.0 9.0 9.0

Example  2. Bar Admiral Pien  Acetic acid salts and Cholecalciferol (40,000,000 IU / g)  Preparation of tablets containing

Tablets containing barmacytials phenacetate and cholecalciferol powder (40,000,000 IU / g) were prepared according to the contents and compositions in Table 2 below. The content of each component in Table 2 represents the refined sugar content (mg). After mixing cholecalciferol and microcrystalline cellulose (about 9.0% by weight of the total amount used), the bar-cleavage phenylacetate (22.6 mg per tablet, 20 mg as bar celecoxib), colloidal silicon dioxide and histidine were added And then microcrystalline cellulose (about 91.0% by weight of the total amount used), pregelatinized starch and starch glycolic acid sodium were further added and mixed. The resulting mixture was sieved with a 30 mesh sieve, and lactose hydrate was added and mixed. The resulting mixture was mixed with sodium stearyl fumarate. The resulting mixture was triturated to produce 290 mg of a tablet. The obtained tablets were coated with Opadry TM 85F42129 (Colorcon) to prepare film-coated tablets.

ingredient EXAMPLES (mg / tablet) 2-1 2-2 2-3 2-4 2-5 2-6 2-7 2-8 2-9 Bar adecinoxyacetate 22.6 22.6 22.6 22.6 22.6 22.6 22.6 22.6 22.6 Cholecalciferol 0.02 0.02 0.02 0.04 0.08 0.14 8.0 0.02 0.02 Pregelatinized starch 45.0 45.0 45.0 45.0 45.0 45.0 45.0 10.0 90.0 Microcrystalline cellulose 89.38 74.38 88.38 89.36 89.32 89.26 88.4 199.38 26.38 Colloidal silicon dioxide 15.0 15.0 9.0 15.0 15.0 15.0 9.0 1.0 1.0 Lactose baggage 85.0 85.0 90.0 85.0 85.0 85.0 82.0 15.0 118.0 Histidine 5.0 20.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 Starch glycolate sodium 20.0 20.0 21.0 20.0 20.0 20.0 21.0 26.0 3.0 Sodium stearyl fumarate 8.0 8.0 9.0 8.0 8.0 8.0 9.0 2.0 15.0 Opadry TM 85F42129 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0

Example  3. Bar Admiral Pien  Acetic acid salts and Cholecalciferol (100,000 IU / g)  Preparation of tablets containing

Tablets containing barmacytial penacetate and cholecalciferol powder (100,000 IU / g) were prepared according to the contents and compositions in Table 3 below. The content of each component in Table 3 represents the refined sugar content (mg). (22.6 mg per tablet, 20 mg as a bar steroid), colloidal silicon dioxide and histidine were mixed and then mixed with concentrated cholecalciferol (8.0 mg per tablet, 800 IU as vitamin D3) Thereafter, microcrystalline cellulose, pregelatinized starch and sodium starch glycolate were further added and mixed. The resulting mixture was sieved with a 30 mesh sieve, and lactose hydrate was added and mixed. The resulting mixture was mixed with sodium stearyl fumarate. The resulting mixture was triturated to produce 290 mg of a tablet. The obtained tablets were coated with Opadry TM 85F42129 (Colorcon) to prepare film-coated tablets.

ingredient EXAMPLES (mg / tablet) 3-1 3-2 3-3 3-4 3-5 3-6 3-7 3-8 3-9 Bar adecinoxyacetate 22.6 22.6 22.6 22.6 22.6 22.6 22.6 22.6 22.6 Cholecalciferol 8.0 8.0 16.0 32.0 40.0 50.0 56.0 0.5 4.0 Pregelatinized starch 45.0 45.0 45.0 45.0 45.0 45.0 45.0 45.0 45.0 Microcrystalline cellulose 88.4 73.4 80.4 64.4 56.4 46.4 40.4 88.4 88.4 Colloidal silicon dioxide 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0 Lactose baggage 82.0 82.0 82.0 82.0 82.0 82.0 82.0 89.5 86.0 Histidine 5.0 20.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 Starch glycolate sodium 21.0 21.0 21.0 21.0 21.0 21.0 21.0 21.0 21.0 Sodium stearyl fumarate 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0 Opadry TM 85F42129 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0

Comparative Example  One. Bar Admiral Pien  Preparation of tablets containing acetic acid salts

(Comparative Example 1-1), inorganic salt of calcium carbonate (Comparative Example 1-2), antioxidant ascorbic acid (Comparative Example 1-3), or butylated hydroxytoluene (Comparative Example 1) instead of histidine, -4) was used in place of the antimicrobial agent, the tablets containing the penic acid acetic acid salt were prepared in the same manner as in Example 1-1. In addition, tablets (Comparative Example 1-5) containing baracetic acid phenacetate were prepared in the same manner as in Example 1-1, except that histidine was not used for comparison. The compositions of Comparative Examples 1-1 to 1-5 are shown in Table 4 below. The content of each component in Table 4 represents the content of refined sugar (mg).

ingredient Comparative Example (mg / Tablet) 1-1 1-2 1-3 1-4 1-5 Bar adecinoxyacetate 22.6 22.6 22.6 22.6 22.6 Pregelatinized starch 45.0 45.0 45.0 45.0 45.0 Microcrystalline cellulose 89.4 89.4 89.4 89.4 94.4 Colloidal silicon dioxide 9.0 9.0 9.0 9.0 9.0 Lactose baggage 90.0 90.0 90.0 90.0 90.0 Meglumine 5.0 - - - - Calcium carbonate - 5.0 - - - Ascorbic acid - - 5.0 - - Butylated hydroxytoluene - - - 5.0 - Starch glycolate sodium 21.0 21.0 21.0 21.0 21.0 Sodium stearyl fumarate 9.0 9.0 9.0 9.0 9.0 Opadry TM 85F42129 9.0 9.0 9.0 9.0 9.0

Comparative Example  2. Bar Admiral Pien  Acetic acid salts and Cholecalciferol  Preparation of tablets containing

(Comparative Example 2-1) which is an amino alcohol instead of histidine, calcium carbonate (Comparative Example 2-2) which is an inorganic salt, ascorbic acid (Comparative Example 2-3) or butylated hydroxytoluene (Comparative Example 2 -4) was used in place of benzalkonium chloride, tablets containing the penic acid acetic acid salt and cholecalciferol were prepared in the same manner as in Example 2-1. In addition, tablets (Comparative Example 2-5) containing a penic acid acetic acid salt and cholecalciferol were prepared in the same manner as in Example 2-1, except that histidine was not used for comparison. The compositions of Comparative Examples 2-1 to 2-5 are shown in Table 5 below. The content of each component in Table 5 represents the refined sugar content (mg).

ingredient Comparative Example (mg / Tablet) 2-1 2-2 2-3 2-4 2-5 Bar adecinoxyacetate 22.6 22.6 22.6 22.6 22.6 Cholecalciferol 0.02 0.02 0.02 0.02 0.02 Pregelatinized starch 45.0 45.0 45.0 45.0 45.0 Microcrystalline cellulose 89.38 89.38 89.38 89.38 93.4 Colloidal silicon dioxide 15.0 15.0 15.0 15.0 15.0 Lactose baggage 85.0 85.0 85.0 85.0 85.0 Meglumine 5.0 - - - - Calcium carbonate - 5.0 - - - Ascorbic acid - - 5.0 - - Butylated hydroxytoluene - - - 5.0 - Starch glycolate sodium 20.0 20.0 20.0 20.0 20.0 Sodium stearyl fumarate 8.0 8.0 8.0 8.0 8.0 Opadry TM 85F42129 9.0 9.0 9.0 9.0 9.0

Test Example  One. Bar Admiral Pien  Evaluation of the stability of tablets containing acetic acid salts

The initial suppositories for the tablets of Example 1-1 and the tablets of Comparative Examples 1-1 to 1-6 were measured and then subjected to the conditions of opening and closing at harsh conditions (60 ° C, 75% RH) , The content of the softening substance derived from the pan-decongestant was measured. The content of the above-mentioned substance was measured by HPLC using standard solution and standard solution. The standard solution was prepared by taking the phenacetate standard as a standard solution in a test solvent (25 mM phosphate buffer + 4.5 mM nucleic acid sulfonic acid (pH 3.0 ± 0.1) / acetonitrile (50:50 ) (v: v). The test solution was prepared by taking 10 tablets each using the above-mentioned sample solvent. The HPLC conditions were as follows.

<HPLC analysis conditions>

- Detector: Ultraviolet absorptiometer (measuring wavelength: 220 nm)

          Photodiode array (measuring wavelength: 200 ~ 350 nm)

- Column: C18, 5 um, 150 X 4.6 mm column

- Column temperature: 30 ° C

- Mobile phase: 25 mM phosphate buffer (pH 3.0) / acetonitrile (68:32) (v / v)

- Flow rate: about 1.5 mL / min

The results of the measurement of the content of the flexible material in the severe condition as described above are shown in Table 6 below.

Contaminant content in harsh conditions (60 ° C, 75% RH) Condition Flexible material Example (mg) Comparative Example (mg) 1-1 1-1 1-2 1-3 1-4 1-5 Open condition


Initial flexible material 0.000 0.000 0.000 0.000 0.000 0.000 Harsh 1 week flexible material 0.235 0.364 0.333 0.423 0.287 0.330 Severe two-week flexible material 0.330 0.781 0.479 0.924 0.812 0.480 Severe 4-note flexible material 0.811 1.213 1.258 1.884 1.166 1.123 Close condition


Initial flexible material 0.000 0.000 0.000 0.000 0.000 0.000 Harsh 1 week flexible material 0.091 0.211 0.151 0.211 0.187 0.227 Severe two-week flexible material 0.105 0.290 0.272 0.440 0.243 0.270 Severe 4-note flexible material 0.194 0.376 0.320 0.772 0.291 0.310

As can be seen from the results of the above Table 6, the tablets of Example 1-1 show a remarkably low production of a flexible substance, while containing an amino alcohol, an inorganic salt, or an antioxidant or containing a stabilizer The tablets of the comparative examples all showed a high content of the flexible material. Therefore, it can be confirmed that the tablets obtained according to the present invention exhibit excellent stability by minimizing the production of a flexible substance.

Test Example  2. Bar Admiral Pien  Acetic acid salts and Cholecalciferol  Evaluation of the stability of tablets containing

The initial suppositories for the tablets of Example 2-1 and the tablets of Comparative Examples 2-1 to 2-6 were measured and then subjected to an open and a close condition at harsh conditions (60 ° C, 75% RH) , The content of the softening substance derived from the pan-decongestant was measured. The content of the above-mentioned flexible substance was measured in the same manner as in Test Example 1, and the results are shown in Table 7 below.

Contaminant content in harsh conditions (60 ° C, 75% RH) Condition Flexible material Example (mg) Comparative Example (mg) 2-1 2-1 2-2 2-3 2-4 2-5 Open condition


Initial flexible material 0.000 0.000 0.000 0.000 0.000 0.000 Harsh 1 week flexible material 0.241 0.364 0.309 0.402 0.265 0.321 Severe two-week flexible material 0.370 0.775 0.429 0.864 0.794 0.465 Severe 4-note flexible material 0.767 1.123 1.111 1.778 1.155 1.143 Close condition


Initial flexible material 0.000 0.000 0.000 0.000 0.000 0.000 Harsh 1 week flexible material 0.084 0.202 0.140 0.199 0.173 0.210 Severe two-week flexible material 0.099 0.284 0.285 0.397 0.235 0.253 Severe 4-note flexible material 0.190 0.356 0.313 0.755 0.285 0.316

As can be seen from the results of Table 7 above, the tablets of Example 2-1 had the remarkably low production of the suppositories as in the tablets of Example 1-1, whereas the tablets of Examples 2-1, The tablets of the comparative examples which did not contain the agent or did not contain the stabilizer all showed a high content of the flexible substance. Therefore, it can be confirmed that the tablets obtained according to the present invention exhibit excellent stability by minimizing the production of a flexible substance.

Claims (14)

A biodegradable ciphen or a pharmaceutically acceptable salt thereof as an active ingredient; And histidine as a stabilizer, and does not comprise an antioxidant. The pharmaceutical composition according to claim 1, which further comprises at least one vitamin D derivative selected from the group consisting of cholecalciferol, calcitriol, calcipotriol, talcitalol, camalcitol, paricalcitol, &Lt; / RTI &gt; 3. The pharmaceutical composition according to claim 1 or 2, wherein the pharmaceutically acceptable salt of the bar-cleansing cine is a penic acid acetic acid salt. 3. The pharmaceutical composition according to claim 2, wherein the vitamin D derivative is cholecalciferol. delete delete 3. The pharmaceutical composition according to claim 1 or 2, wherein the histidine is present in an amount of 0.1 to 20.0% by weight based on the total weight of the composition. 8. The pharmaceutical composition according to claim 7, wherein the histidine is present in the range of 0.5 to 5% by weight based on the total weight of the composition. The method according to claim 1 or 2, wherein the lactose is selected from the group consisting of lactose, mannitol, isomalt, microcrystalline cellulose, dextran, maltodextrin, sorbitol, glucose, pregelatinized starch, potato starch, corn starch, light anhydrous silicic acid, colloidal silicon dioxide, A diluent selected from the group consisting of cellulose, anhydrous calcium phosphate, carboxymethylcellulose, carboxyethylcellulose, hydroxyethylcellulose, and magnesium aluminum silicate; At least one disintegrant selected from the group consisting of starch, pregelatinized starch, sodium starch glycolate, croscarmellose sodium, crospovidone, carboxymethylcellulose calcium, carboxymethylcellulose sodium, alginic acid, and sodium alginate; And stearic acid or its salts, talc, magnesium / aluminum silicate, glyceryl behenate, hard castor oil, vegetable castor oil, polyethylene glycol, glyceryl monostearate, and sucrose stearic acid Wherein the composition further comprises at least one selected from the group consisting of esters. 3. The pharmaceutical composition according to claim 1 or 2, which has the form of a tablet. 11. The pharmaceutical composition according to claim 10, wherein the tablet is further film coated. The pharmaceutical composition according to claim 1, which comprises 22.6 mg of the penic acid acetic acid salt, 10.0 to 90.0 mg of pregelatinized starch, 26.4 to 199.4 mg of microcrystalline cellulose, 1.0 to 15.0 mg of colloidal silicon dioxide, 15.0 to 131.1 mg of lactose monohydrate, To 20.0 mg, sodium starch glycolate 3.0 to 26.0 mg, and sodium stearyl fumarate 2.0 to 15.0 mg. The pharmaceutical composition according to claim 2, which comprises 22.6 mg of the penic acid acetic acid salt per block, 800 to 5600 IU of cholecalciferol, 10.0 to 90.0 mg of pregelatinized starch, 26.38 to 199.38 mg of microcrystalline cellulose, 1.0 to 15.0 mg of colloidal silicon dioxide, Wherein the composition comprises 15.0 to 118.0 mg of lactose hydrate, 0.5 to 20.0 mg of histidine, 3.0 to 26.0 mg of sodium starch glycolate, and 2.0 to 15.0 mg of sodium stearyl fumarate. The pharmaceutical composition according to claim 12 or 13, wherein a film coating layer containing polyvinyl alcohol is formed on the tablet.
KR1020170063942A 2017-05-24 2017-05-24 Pharmaceutical composition comprising bazedoxifene or a pharmaceutically acceptable salt thereof KR101940569B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020170063942A KR101940569B1 (en) 2017-05-24 2017-05-24 Pharmaceutical composition comprising bazedoxifene or a pharmaceutically acceptable salt thereof
PCT/KR2018/005470 WO2018216933A1 (en) 2017-05-24 2018-05-14 Pharmaceutical composition containing bazedoxifene or pharmaceutically acceptable salt

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020170063942A KR101940569B1 (en) 2017-05-24 2017-05-24 Pharmaceutical composition comprising bazedoxifene or a pharmaceutically acceptable salt thereof

Publications (2)

Publication Number Publication Date
KR20180128612A KR20180128612A (en) 2018-12-04
KR101940569B1 true KR101940569B1 (en) 2019-01-21

Family

ID=64396660

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020170063942A KR101940569B1 (en) 2017-05-24 2017-05-24 Pharmaceutical composition comprising bazedoxifene or a pharmaceutically acceptable salt thereof

Country Status (2)

Country Link
KR (1) KR101940569B1 (en)
WO (1) WO2018216933A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104013630A (en) * 2014-05-23 2014-09-03 合肥九研医药科技开发有限公司 Compound bazedoxifene acetate estrogen composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04011634A (en) * 2002-06-13 2005-07-05 Wyeth Corp Bazedoxifene treatment regimens.
AR056471A1 (en) * 2005-08-24 2007-10-10 Wyeth Corp BAZEDOXIFEN ACETATE FORMULATIONS
CN101977897A (en) * 2008-02-11 2011-02-16 惠氏有限责任公司 Methods of preparing polymorphic form a of bazedoxifene acetate
KR101806782B1 (en) * 2015-09-07 2018-01-10 주식회사 경보제약 Method for the preparation of high purity Bazedoxifene Acetate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104013630A (en) * 2014-05-23 2014-09-03 合肥九研医药科技开发有限公司 Compound bazedoxifene acetate estrogen composition

Also Published As

Publication number Publication date
KR20180128612A (en) 2018-12-04
WO2018216933A1 (en) 2018-11-29

Similar Documents

Publication Publication Date Title
EP1309327B1 (en) Pharmaceutical compositions of estrogenic agents
US8420662B2 (en) Stable solid preparation containing 4,5-epoxymorphinan derivative
US20100172995A1 (en) Process For Preparing A Solid Pharmaceutical Composition
US10350194B2 (en) Pharmaceutical composition containing an arylalkylamine compound
CA2989534A1 (en) Stable pharmaceutical composition for oral administration
EP1965773B1 (en) Oral formulation of anhydrous olanzapine form i
US11344535B2 (en) Pharmaceutical composition
JP4972563B2 (en) New film-coated tablets
KR20180036633A (en) Composite capsules with improved dissolution rate comprising raloxifene, and Vitamin D or its derivatives,and preparing method thereof
KR101940569B1 (en) Pharmaceutical composition comprising bazedoxifene or a pharmaceutically acceptable salt thereof
KR102427007B1 (en) Solid formulation with improved photostability
EP2101742B1 (en) Pharmaceutical composition containing clopidogrel hydrogenesulphate of polymorph 1 form
EP2303233B1 (en) Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof
EP2095815B1 (en) Pharmaceutical formulations containing clopidogrel
EP3505158A1 (en) Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt
US20090186083A1 (en) Method for stabilization of isoxazole compound
JP2018145095A (en) Pharmaceutical composition containing erlotinib hydrochloride
JP2012201597A (en) Solid preparation comprising mosapride
US10471156B2 (en) Pharmaceutical composition comprising amorphous lenalidomide
AU2013223749A1 (en) Stable dosage forms of imatinib mesylate
US20100178338A1 (en) Stabilized pharmaceutical compositions comprising atorvastatin
RU2589701C1 (en) Pharmaceutical composition for oral administration with improved solubility and/or absorbability
JP5065519B1 (en) Method for producing crystalline atorvastatin calcium-containing tablet
KR20180003340A (en) Solid formulation for oral administration containing amorphous solifenacin and a process for the preparation thereof
EP4074313A1 (en) Solid pharmaceutical preparation

Legal Events

Date Code Title Description
E701 Decision to grant or registration of patent right
GRNT Written decision to grant